Royal Bank of Canada
ONCY

Royal Bank of Canada’s Oncolytics Biotech ONCY Stock Holding History

Royal Bank of Canada’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68,311
Closed -$60K – 7517
2025
Q4 		$60K Buy
68,311
+78
+0.1% +$84 ﹤0.01% 5468
2025
Q3 		$96K Buy
68,233
+9,721
+17% +$10.9K ﹤0.01% 5531
2025
Q2 		$45K Sell
58,512
-8,598
-13% -$4.55K ﹤0.01% 5972
2025
Q1 		$37K Buy
67,110
+3,428
+5% +$2.51K ﹤0.01% 5679
2024
Q4 		$58K Sell
63,682
-10,864
-15% -$11.3K ﹤0.01% 5615
2024
Q3 		$65K Buy
74,546
+12,279
+20% +$12.1K ﹤0.01% 5577
2024
Q2 		$62K Buy
62,267
+1,234
+2% +$1.34K ﹤0.01% 5544
2024
Q1 		$65K Buy
61,033
+6,108
+11% +$6.83K ﹤0.01% 5415
2023
Q4 		$74K Sell
54,925
-804
-1% -$1.26K ﹤0.01% 5789
2023
Q3 		$121K Buy
55,729
+2,524
+5% +$6.17K ﹤0.01% 5258
2023
Q2 		$138K Sell
53,205
-451
-0.8% -$749 ﹤0.01% 5073
2023
Q1 		$64K Buy
53,656
+7,222
+16% +$11.3K ﹤0.01% 5485
2022
Q4 		$76K Sell
46,434
-2,406
-5% -$3.65K ﹤0.01% 5646
2022
Q3 		$60K Buy
48,840
+5,153
+12% +$6.31K ﹤0.01% 5644
2022
Q2 		$44K Sell
43,687
-1,359
-3% -$1.65K ﹤0.01% 5772
2022
Q1 		$71K Buy
45,046
+3,570
+9% +$5.99K ﹤0.01% 5862
2021
Q4 		$58K Buy
41,476
+921
+2% +$1.7K ﹤0.01% 6293
2021
Q3 		$85K Buy
40,555
+3,903
+11% +$8.84K ﹤0.01% 5823
2021
Q2 		$102K Buy
36,652
+9,271
+34% +$28.4K ﹤0.01% 5592
2021
Q1 		$105K Sell
27,381
-8,201
-23% -$24.5K ﹤0.01% 5428
2020
Q4 		$84K Buy
35,582
+4,963
+16% +$11.9K ﹤0.01% 5429
2020
Q3 		$52K Sell
30,619
-25,864
-46% -$47.4K ﹤0.01% 5323
2020
Q2 		$106K Buy
56,483
+1,507
+3% +$2.84K ﹤0.01% 4821
2020
Q1 		$75K Sell
54,976
-5,189
-9% -$13K ﹤0.01% 4938
2019
Q4 		$286K Buy
60,165
+48,610
+421% +$54.9K ﹤0.01% 4379
2019
Q3 		$7K Buy
11,555
+251
+2% +$256 ﹤0.01% 5900
2019
Q2 		$19K Sell
11,304
-3,911
-26% -$7.1K ﹤0.01% 5745
2019
Q1 		$28K Buy
15,215
+7,324
+93% +$14.8K ﹤0.01% 5490
2018
Q4 		$14K Sell
7,891
-4,371
-36% -$11.8K ﹤0.01% 5738
2018
Q3 		$47K Buy
12,262
+3,363
+38% +$15.6K ﹤0.01% 5261
2018
Q2 		$49K Buy
+8,899
New +$54.8K ﹤0.01% 5164

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Royal Bank of Canada's ONCY Position: Q1 2026 in Review

Royal Bank of Canada sold out of Oncolytics Biotech (ONCY) in Q1 2026, closing a stake of 68,311 shares — an estimated $60K sold.

Royal Bank of Canada first reported a position in ONCY in Q2 2018 and held it in 31 quarters. The position peaked at $286K in Q4 2019. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Royal Bank of Canada reported no remaining Oncolytics Biotech position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 68,311 Oncolytics Biotech shares in Q1 2026, an estimated $60K.
  • Royal Bank of Canada first reported a position in Oncolytics Biotech in Q2 2018 and held it in 31 quarters.
  • Royal Bank of Canada's Oncolytics Biotech position peaked at $286K in Q4 2019.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.